BMB Reports

생화학분자생물학회 (Korean Society for Biochemistry and Molecular Biology)
권호 표지
DOI QR코드

DOI QR Code

Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway

  • Chaojin Hong (Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College) ;
  • Yimei Meng (Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College) ;
  • Anchen Qiu (Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College) ;
  • Haibo Zhang (Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College) ;
  • Liu Yang (Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College) ;
  • Yupeng Hong (Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College) ;
  • Yumei Huang (Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College)
  • 투고 : 2024.03.02
  • 심사 : 2024.05.30
  • 발행 : 2024.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Lung cancer is one of the most significant malignancies, with both high morbidity and mortality. CDK10 is closely related to cancer progression and metastasis. However, its role in lung cancer radioresistance demands further clarification. In this study, we demonstrated that CDK10 was downregulated in lung cancer tissues, and CDK10 expression level was associated with the clinical prognosis in lung cancer patients. We also found that silencing CDK10 promoted lung cancer cell proliferation, migration, and radioresistance. We further verified that silencing CDK10 facilitated the activation of JNK/c-Jun signaling, and c-Jun depletion could reverse the effects of CDK10 knockdown in lung cancer cells. Our findings revealed that CDK10 plays an important role in cell growth and radioresistance by inhibiting JNK/c-Jun signaling pathway in lung cancer. Therefore, CDK10 might be a promising therapeutic target in lung cancer.

키워드

과제정보

This work was supported by the Zhejiang Provincial Natural Science Foundation of China (Grant number: LQ22H160014) and the National Natural Science Foundation of China (Grant number: 82102816).

참고문헌

  1. Siegel RL, Giaquinto AN and Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74, 12-49 
  2. Herbst RS, Morgensztern D and Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553, 446-454 
  3. Lahiri A, Maji A, Potdar PD et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22, 40 
  4. Beaty BT and Weiner AA (2020) Alternatives to surgery for early-stage non-small cell lung cancer: stereotactic radiotherapy. Clin Chest Med 41, 185-195 
  5. Tini P, Nardone V, Pastina P, Pirtoli L, Correale P and Giordano A (2018) The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer. Expert Rev Anticancer Ther 18, 593-602 
  6. Yu J, Zhang W, Lu B et al (2018) miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M. Oncol Lett 15, 3305-3312 
  7. Khanal P, Yun HJ, Lim SC et al (2012) Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells. Oncogene 31, 3845-3856 
  8. Zhang X, Zhao Y, Yiminniyaze R et al (2023) CDK10 suppresses metastasis of lung adenocarcinoma through inhibition of the ETS2/c-Raf/p-MEK/p-ERK signaling loop. Mol Carcinog 63, 61-74 
  9. Li H, You Y and Liu J (2018) Cyclin‑dependent kinase 10 prevents glioma metastasis via modulation of Snail expression. Mol Med Rep 18, 1165-1170 
  10. You Y, Yang W, Wang Z et al (2013) Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. Cell Oncol (Dordr) 36, 323-331 
  11. Zhong XY, Xu XX, Yu JH et al (2012) Clinical and biological significance of Cdk10 in hepatocellular carcinoma. Gene 498, 68-74 
  12. Zhao BW, Chen S, Li YF et al (2017) Low expression of CDK10 correlates with adverse prognosis in gastric carcinoma. J Cancer 8, 2907-2914 
  13. You Y, Li H, Qin X et al (2015) Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report. Cell Oncol (Dordr) 38, 485-491 
  14. Yu JH, Zhong XY, Zhang WG et al (2012) CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol Rep 27, 1266-1276 
  15. Iorns E, Turner NC, Elliott R et al (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91-104 
  16. Weiswald LB, Hasan MR, Wong JCT et al (2017) Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2. Mol Cancer Ther 16, 2292-2303 
  17. Kumar A, Singh UK, Kini SG et al (2015) JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem 7, 2065-2086 
  18. Zhang D, Jiang Q, Ge X et al (2021) RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway. Int J Biol Sci 17, 2622-2632 
  19. Jiao CY, Feng QC, Li CX et al (2021) BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways. Cell Death Dis 12, 63 
  20. Liu Y, Sui A, Sun J, Wu Y, Liu F and Yang Y (2023) c-Jun-mediated JMJD6 restoration enhances resistance of liver cancer to radiotherapy through the IL-4-activated ERK pathway. Cell Biol Int 47, 1392-1405 
  21. Sun Y, Chen K, Lin G, Wan F, Chen L and Zhu X (2021) Silencing c-Jun inhibits autophagy and abrogates radioresistance in nasopharyngeal carcinoma by activating the PI3K/AKT/mTOR pathway. Ann Transl Med 9, 1085 
  22. Barker HE, Paget JT, Khan AA and Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15, 409-425 
  23. Vinod SK and Hau E (2020) Radiotherapy treatment for lung cancer: current status and future directions. Respirology 25 Suppl 2, 61-71 
  24. Olivares-Urbano MA, Grinan-Lison C, Marchal JA and Nunez MI (2020) CSC radioresistance: a therapeutic challenge to improve radiotherapy effectiveness in cancer. Cells 9, 1651 
  25. Bazzi ZA and Tai IT (2021) CDK10 in gastrointestinal cancers: dual roles as a tumor suppressor and oncogene. Front Oncol 11, 655479 
  26. You Y, Bai F, Ye Z et al (2018) Downregulated CDK10 expression in gastric cancer: association with tumor progression and poor prognosis. Mol Med Rep 17, 6812-6818 
  27. Huang RX and Zhou PK (2020) DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 5, 60 
  28. Vasireddy RS, Sprung CN, Cempaka NL, Chao M and McKay MJ (2010) H2AX phosphorylation screen of cells from radiosensitive cancer patients reveals a novel DNA double-strand break repair cellular phenotype. Br J Cancer 102, 1511-1518 
  29. Wang Y, Wang J, Zhao A, Huang X and Zhang X (2022) HPV16 E6E7 up-regulates KIF2A expression by activating JNK/c-Jun signal, is beneficial to migration and invasion of cervical cancer cells. Open Med (Wars) 17, 1780-1787 
  30. Qiao GB, Wang RT, Wang SN, Tao SL, Tan QY and Jin H (2021) GRP75-mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c-JUN signaling. Thorac Cancer 12, 1558-1569 
  31. Budwit-Novotny DA, McCarty KS, Cox EB et al (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46, 5419-5425